Cumberland Pharmaceuticals Inc.
CPIX
$5.72
-$0.14-2.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.13M | 9.55M | 8.29M | 10.84M | 11.71M |
| Total Other Revenue | -- | 4.13M | -- | -- | -- |
| Total Revenue | 9.13M | 13.68M | 8.29M | 10.84M | 11.71M |
| Cost of Revenue | 1.93M | 2.24M | 988.80K | 2.01M | 1.43M |
| Gross Profit | 7.20M | 11.44M | 7.30M | 8.83M | 10.29M |
| SG&A Expenses | 7.62M | 10.25M | 7.01M | 7.10M | 6.70M |
| Depreciation & Amortization | 1.25M | 1.01M | 1.01M | 1.01M | 1.01M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.26M | 15.05M | 10.26M | 11.58M | 10.42M |
| Operating Income | -3.13M | -1.37M | -1.97M | -747.50K | 1.29M |
| Income Before Tax | -3.28M | -1.41M | -1.94M | -729.50K | 1.25M |
| Income Tax Expenses | 3.90K | 23.20K | 5.70K | 5.70K | 5.70K |
| Earnings from Continuing Operations | -3.29M | -1.43M | -1.95M | -735.20K | 1.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.60K | 17.00K | 8.30K | -5.50K | 8.90K |
| Net Income | -3.29M | -1.41M | -1.94M | -740.70K | 1.26M |
| EBIT | -3.13M | -1.37M | -1.97M | -747.50K | 1.29M |
| EBITDA | -1.85M | -329.30K | -927.50K | 286.40K | 2.32M |
| EPS Basic | -0.22 | -0.09 | -0.13 | -0.05 | 0.08 |
| Normalized Basic EPS | -0.13 | -0.06 | -0.08 | -0.03 | 0.05 |
| EPS Diluted | -0.22 | -0.09 | -0.13 | -0.05 | 0.08 |
| Normalized Diluted EPS | -0.13 | -0.06 | -0.08 | -0.03 | 0.05 |
| Average Basic Shares Outstanding | 14.96M | 14.96M | 14.96M | 14.96M | 14.94M |
| Average Diluted Shares Outstanding | 14.96M | 14.96M | 14.96M | 14.96M | 15.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |